Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 232

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 232
---
. Clancy is currently a visiting senior
lecturer of Finance at Cornell University’s Graduate School of Management, where he has been employed since August 2020, and has been an executive fellow at Harvard Business School since July 2020. Previously, Mr. Clancy served as
executive vice president and senior advisor at Alexion Pharmaceutical, Inc. (NASDAQ: ALXN) from November 2019 to July 2020 and executive vice president and chief financial officer from July 2017 to October 2019. Mr. Clancy also served as
executive vice president and chief financial officer of Biogen, Inc. (NASDAQ: BIIB) from August 2007 to June 2017. Mr. Clancy also serves on the boards of directors of Exact Sciences Corporation (NASDAQ: EXAS), since March 2021, Xilio
Therapeutics, Inc. (NASDAQ: XLO), since July 2020, and Incyte Corporation (NASDAQ: INCY), since 2015. Mr. Clancy previously served on the board of directors of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from September 2013 to June 2023.
Mr. Clancy earned a B.S. in finance from Babson College and an M.B.A. from Columbia University. We believe Mr. Clancy’s significant financial background in the biopharmaceutical industry and experience as a public company board member
provides him with the appropriate set of skills to serve as a member of our board of directors.

H. Edward Fleming, Jr., M.D., has
served as a member of our board of directors since March 2024. Dr. Fleming joined Enavate Sciences in November 2022 and serves as executive vice president of commercialization, investing in and building therapeutic companies. Previously, in
2022, Dr. Fleming retired from McKinsey & Company, where he worked for 26 years in various roles, including senior partner, global leader of research and development and senior advisor. Dr. Fleming has also served on the boards of
directors of Upstream Bio, Inc. (NASDAQ: UPB) since June 2023 and of CRISPR Therapeutics AG (NASDAQ: CRSP) since June 2021. In addition, Dr. Fleming is a member of the boards of directors of several private companies, including Komodo Health,
Inc., Orso Bio, Inc., Sudo Biosciences, Inc. and Egnite,